Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Transphorm, Inc. | tgan-20200811.htm |
Exhibit 99.1
Transphorm Reports Second Quarter 2020 Results
GOLETA, Calif.—August 11, 2020—Transphorm, Inc. (“Transphorm” or the “Company”) (OTCQB: TGAN), a pioneer in the development and manufacturing of high reliability, high performance gallium nitride (GaN) power semiconductors, today announced financial results for the second quarter ended June 30, 2020.
First Half 2020 & Recent Business Highlights
•Introduced SuperGaN™ Power FETs with launch of Gen IV GaN platform
•Partnered with Microchip Technology Inc. to combine high reliability GaN with a digital signal controller in support of accelerating GaN adoption
•Announced Hangzhou Zhongheng Electric Co. development of an ultra-efficient, GaN-based power module using Transphorm’s GaN devices
•Raised $19.7 million in net proceeds from a private placement of common stock in February
•Successfully listed common stock on the OTC market and recently granted DTC eligibility
Second Quarter 2020 Financial Highlights
•Revenue increased to $6.3 million, including $5.0 million of licensing revenue
•Net loss was $2.3 million, or ($0.06) per share
•Cash and equivalents were $9.4 million at quarter-end
“We are very pleased with the progress we demonstrated during the second quarter,” said Mario Rivas, Transphorm’s CEO. “We continue to successfully expand our comprehensive portfolio of high-voltage GaN power conversion devices, while working to drive increased adoption of our products for targeted applications, including the emerging opportunity in fast charging power adapters. Although the COVID-19 pandemic has impacted certain customers, resulting in delays of their internal development programs that could adversely affect the pace of adoption and revenue in the near-term, we are confident that our pipeline of customer engagements and design wins will drive future long-term growth.”
Second Quarter of 2020 Results
Revenue increased to $6.3 million, compared to $1.1 million in the first quarter of 2020 and $0.5 million in the second quarter of 2019. Second quarter 2020 revenue included $5.0 million of licensing revenue from a manufacturing partner, Nexperia, related to funding of technology development, as well as $0.7 million from the Company’s three-year contract with the U.S. Navy. For the first six months of 2020, revenue was $7.4 million as compared to $1.0 million in the prior year period.
Operating expenses were $4.2 million in the second quarter, compared to $5.1 million in the prior quarter and $4.2 million in the second quarter of 2019. Second quarter 2020 operating expenses consisted of R&D expenses of $1.6 million and SG&A expenses of $2.6 million.
Net loss for the second quarter of 2020 was $2.3 million, or ($0.06) per share, compared to a net loss of $4.2 million, or ($0.13) per share, in the prior quarter and a net loss of $5.9 million, or ($0.21) per share, in the second quarter of 2019.
Cash and equivalents as of June 30, 2020 were $9.4 million, compared to $14.6 million as of March 31, 2020.
About Transphorm
Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry’s first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company’s vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm’s innovations are moving power electronics beyond the limitations of silicon to achieve over 99% efficiency, 40% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the successful execution and continuity of Company partnerships and customer engagements, the Company’s technology and product offerings, industry acceptance of GaN technology, the Company’s pipeline and future anticipated growth. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: risks related to Transphorm’s operations, such as additional financing requirements and access to capital; competition; the ability of Transphorm to protect its intellectual property rights; and other risks set forth in the Company’s filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Shelton Group
Brett Perry | Leanne Sievers
1-214-272-0070 | 1-949-224-3874
sheltonir@sheltongroup.com
Company Contact:
Cameron McAulay
Chief Financial Officer
1-805-456-1300 ext. 140
cmcaulay@transphormusa.com
Transphorm, Inc.
Condensed Consolidated Balance Sheets
(in thousands except share and per share data)
June 30, 2020 (Unaudited) | December 31, 2019 | |||||||||||||||||||
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | $ | 9,382 | $ | 2,875 | ||||||||||||||||
| Accounts receivable, net, including related parties | 769 | 709 | ||||||||||||||||||
| Inventory | 1,342 | 990 | ||||||||||||||||||
| Prepaid expenses and other current assets | 1,828 | 783 | ||||||||||||||||||
| Total current assets | 13,321 | 5,357 | ||||||||||||||||||
| Property and equipment, net | 1,533 | 1,770 | ||||||||||||||||||
| Goodwill | 1,336 | 1,325 | ||||||||||||||||||
| Intangible assets, net | 1,136 | 1,313 | ||||||||||||||||||
| Other assets | 417 | 497 | ||||||||||||||||||
| Total assets | $ | 17,743 | $ | 10,262 | ||||||||||||||||
| Liabilities, convertible preferred stock and stockholders’ deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses | $ | 1,664 | $ | 2,383 | ||||||||||||||||
| Deferred revenue | 193 | — | ||||||||||||||||||
| Development loan | 10,000 | 5,000 | ||||||||||||||||||
| Revolving credit facility, including accrued interest | 10,762 | 10,458 | ||||||||||||||||||
| Unfunded commitment to joint venture | 1,548 | 1,688 | ||||||||||||||||||
| Accrued payroll and benefits | 1,348 | 1,159 | ||||||||||||||||||
| Total current liabilities | 25,515 | 20,688 | ||||||||||||||||||
| Development loans, net of current portion | — | 10,000 | ||||||||||||||||||
| Promissory note | 15,580 | 16,169 | ||||||||||||||||||
| Total liabilities | 41,095 | 46,857 | ||||||||||||||||||
| Commitments and contingencies | ||||||||||||||||||||
| Convertible preferred stock: | ||||||||||||||||||||
| Series 1, $0.0001 par value; no shares authorized, issued and outstanding as of June 30, 2020; 12,438,704 shares authorized and 12,433,953 shares issued and outstanding as of December 31, 2019 | — | 39,658 | ||||||||||||||||||
| Series 2, $0.0001 par value; no shares authorized, issued and outstanding as of June 30, 2020; 7,507,699 shares authorized and 7,499,996 shares issued and outstanding as of December 31, 2019 | — | 30,000 | ||||||||||||||||||
| Series 3, $0.0001 par value; no shares authorized, issued and outstanding as of June 30, 2020; 4,000,000 shares authorized, issued and outstanding as of December 31, 2019 | — | 16,000 | ||||||||||||||||||
| Total convertible preferred stock | — | 85,658 | ||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Common stock, $0.0001 par value; 750,000,000 shares authorized and 35,135,520 shares issued and outstanding as of June 30, 2020; 29,012,034 shares authorized and 4,220,998 shares issued and outstanding as of December 31, 2019 | 4 | — | ||||||||||||||||||
| Additional paid-in capital | 127,787 | 22,404 | ||||||||||||||||||
| Accumulated deficit | (150,372) | (143,915) | ||||||||||||||||||
| Accumulated other comprehensive loss | (771) | (742) | ||||||||||||||||||
| Total stockholders’ deficit | (23,352) | (122,253) | ||||||||||||||||||
| Total liabilities, convertible preferred stock and stockholders’ deficit | $ | 17,743 | $ | 10,262 | ||||||||||||||||
Transphorm, Inc.
Condensed Consolidated Statements of Operations (unaudited)
(in thousands except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||||||||||||||||||||||||||||||
| Revenue, net, including related parties | $ | 6,329 | $ | 488 | $ | 7,429 | $ | 1,017 | ||||||||||||||||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||
| Cost of goods sold | 1,248 | 1,182 | 2,703 | 2,586 | ||||||||||||||||||||||||||||||||||||||||
| Research and development | 1,594 | 2,022 | 3,060 | 4,204 | ||||||||||||||||||||||||||||||||||||||||
| Sales and marketing | 528 | 675 | 1,046 | 1,526 | ||||||||||||||||||||||||||||||||||||||||
| General and administrative | 2,058 | 1,494 | 5,150 | 2,745 | ||||||||||||||||||||||||||||||||||||||||
| Total operating expenses | 5,428 | 5,373 | 11,959 | 11,061 | ||||||||||||||||||||||||||||||||||||||||
| Income (loss) from operations | 901 | (4,885) | (4,530) | (10,044) | ||||||||||||||||||||||||||||||||||||||||
| Interest expense | 189 | 189 | 378 | 376 | ||||||||||||||||||||||||||||||||||||||||
| Loss in joint venture | 1,856 | 1,100 | 3,275 | 2,227 | ||||||||||||||||||||||||||||||||||||||||
| Changes in fair value of promissory note | 1,658 | 51 | (663) | 84 | ||||||||||||||||||||||||||||||||||||||||
| Other income, net | (532) | (324) | (1,063) | (460) | ||||||||||||||||||||||||||||||||||||||||
| Loss before tax expense | (2,270) | (5,901) | (6,457) | (12,271) | ||||||||||||||||||||||||||||||||||||||||
| Tax expense | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | (2,270) | $ | (5,901) | $ | (6,457) | $ | (12,271) | ||||||||||||||||||||||||||||||||||||
| Net loss per share - basic and diluted | $ | (0.06) | $ | (0.21) | $ | (0.19) | $ | (0.44) | ||||||||||||||||||||||||||||||||||||
| Weighted average common shares outstanding - basic and diluted | 35,135,520 | 28,153,555 | 33,523,844 | 28,153,555 | ||||||||||||||||||||||||||||||||||||||||
Transphorm, Inc.
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Six Months Ended June 30, | ||||||||||||||||||||
| 2020 | 2019 | |||||||||||||||||||
| Cash flows from operating activities: | ||||||||||||||||||||
| Net loss | $ | (6,457) | $ | (12,271) | ||||||||||||||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||||||
| Inventory write-off | 162 | — | ||||||||||||||||||
| Depreciation and amortization | 438 | 615 | ||||||||||||||||||
| Licensing revenue from a related party | (5,000) | — | ||||||||||||||||||
| Stock-based compensation | 236 | 276 | ||||||||||||||||||
| Interest cost | 378 | 376 | ||||||||||||||||||
| Loss in joint venture | 3,275 | 2,227 | ||||||||||||||||||
| Changes in fair value of promissory note | (663) | 84 | ||||||||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||||||||
| Accounts receivable | (60) | (10) | ||||||||||||||||||
| Inventory | (514) | (277) | ||||||||||||||||||
| Prepaid expenses and other current assets | (1,050) | 4 | ||||||||||||||||||
| Other assets | 80 | (61) | ||||||||||||||||||
| Accounts payable and accrued expenses | (719) | (473) | ||||||||||||||||||
| Deferred revenue | 193 | 3,000 | ||||||||||||||||||
| Accrued payroll and benefits | 189 | 44 | ||||||||||||||||||
| Net cash used in operating activities | (9,512) | (6,466) | ||||||||||||||||||
| Cash flows from investing activities: | ||||||||||||||||||||
| Purchases of property and equipment | (22) | (116) | ||||||||||||||||||
| Investment in joint venture | (3,427) | (1,103) | ||||||||||||||||||
| Net cash used in investing activities | (3,449) | (1,219) | ||||||||||||||||||
| Cash flows from financing activities: | ||||||||||||||||||||
| Proceeds from development loans | — | 9,000 | ||||||||||||||||||
| Proceeds from stock option exercise | 18 | — | ||||||||||||||||||
| Payment for repurchase of common stock | (211) | — | ||||||||||||||||||
| Loan repayment | (50) | — | ||||||||||||||||||
| Proceeds from issuance of common stock, net of offering cost | 19,741 | — | ||||||||||||||||||
| Net cash provided by financing activities | 19,498 | 9,000 | ||||||||||||||||||
| Effect of foreign exchange rate changes on cash and cash equivalents | (30) | 14 | ||||||||||||||||||
| Net increase in cash and cash equivalents | 6,507 | 1,329 | ||||||||||||||||||
| Cash and cash equivalents at beginning of period | 2,875 | 3,069 | ||||||||||||||||||
| Cash and cash equivalents at end of period | $ | 9,382 | $ | 4,398 | ||||||||||||||||
| Supplemental disclosures of cash flow information: | ||||||||||||||||||||
| Interest expense paid | $ | — | $ | 496 | ||||||||||||||||
| Supplemental non-cash financing activity: | ||||||||||||||||||||
| Development loan reduction related to licensing revenue | $ | 5,000 | $ | — | ||||||||||||||||